Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15480652 | 0.90 | HDAC6 (0.56) | HDAC1HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL15480654 | 0.88 | HDAC6 (0.72) | HDAC1HDAC6HDAC8HDAC3HDAC7 | |
| SCHEMBL4659287 | 0.87 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL4659080 | 0.87 | HDAC6 (0.67) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL9001651 | 0.86 | KMT2A (0.69) | HTTNR1H3NR1H2KMT2AKDM4E | |
| SCHEMBL5722247 | 0.85 | PTPN1 (0.64) | HDAC6HDAC8HDAC2HSD17B10HTT | |
| SCHEMBL4654851 | 0.84 | HDAC1 (0.69) | HDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL4657405 | 0.84 | HDAC1 (0.69) | HDAC1HDAC6HDAC8HDAC3 | |
| SCHEMBL15482285 | 0.83 | HDAC6 (0.59) | HDAC1HDAC6HDAC8ALOX15HSD17B10 | |
| SCHEMBL4657802 | 0.83 | HDAC6 (0.64) | HDAC1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | claimed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | claimed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | claimed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | claimed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | claimed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | claimed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | disclosed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | disclosed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | disclosed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 4/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 4/4885 |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | HDAC7, SIRT7, HCAR1 | HDAC1 67/4885HDAC6 201/4885HDAC8 72/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.